Bifogade filer
Kurs
+0,83%
Likviditet
185 MSEK
Kalender
Tid* | ||
2025-04-22 | N/A | Årsstämma |
2025-01-28 | 08:00 | Bokslutskommuniké 2024 |
2024-10-18 | - | Kvartalsrapport 2024-Q3 |
2024-07-18 | - | Kvartalsrapport 2024-Q2 |
2024-04-23 | - | X-dag ordinarie utdelning GETI B 4.40 SEK |
2024-04-22 | - | Årsstämma |
2024-04-22 | - | Kvartalsrapport 2024-Q1 |
2024-02-01 | - | Bokslutskommuniké 2023 |
2023-10-23 | - | Kvartalsrapport 2023-Q3 |
2023-07-18 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | X-dag ordinarie utdelning GETI B 4.25 SEK |
2023-04-26 | - | Årsstämma |
2023-04-26 | - | Kvartalsrapport 2023-Q1 |
2023-02-01 | - | Bokslutskommuniké 2022 |
2022-10-19 | - | Kvartalsrapport 2022-Q3 |
2022-07-19 | - | Kvartalsrapport 2022-Q2 |
2022-04-27 | - | X-dag ordinarie utdelning GETI B 4.00 SEK |
2022-04-26 | - | Årsstämma |
2022-04-26 | - | Kvartalsrapport 2022-Q1 |
2022-01-28 | - | Bokslutskommuniké 2021 |
2021-10-20 | - | Kvartalsrapport 2021-Q3 |
2021-07-16 | - | Kvartalsrapport 2021-Q2 |
2021-04-21 | - | X-dag ordinarie utdelning GETI B 3.00 SEK |
2021-04-20 | - | Årsstämma |
2021-04-20 | - | Kvartalsrapport 2021-Q1 |
2021-01-28 | - | Bokslutskommuniké 2020 |
2020-10-16 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-06-29 | - | X-dag ordinarie utdelning GETI B 1.50 SEK |
2020-06-26 | - | Årsstämma |
2020-04-22 | - | Kvartalsrapport 2020-Q1 |
2020-01-30 | - | Bokslutskommuniké 2019 |
2019-10-18 | - | Kvartalsrapport 2019-Q3 |
2019-07-17 | - | Kvartalsrapport 2019-Q2 |
2019-04-24 | - | X-dag ordinarie utdelning GETI B 1.00 SEK |
2019-04-23 | - | Årsstämma |
2019-04-23 | - | Kvartalsrapport 2019-Q1 |
2019-01-30 | - | Bokslutskommuniké 2018 |
2018-10-18 | - | Kvartalsrapport 2018-Q3 |
2018-07-17 | - | Kvartalsrapport 2018-Q2 |
2018-04-27 | - | X-dag ordinarie utdelning GETI B 1.50 SEK |
2018-04-26 | - | Årsstämma |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-01-29 | - | Bokslutskommuniké 2017 |
2017-10-18 | - | Kvartalsrapport 2017-Q3 |
2017-07-17 | - | Kvartalsrapport 2017-Q2 |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-03-30 | - | X-dag ordinarie utdelning GETI B 2.00 SEK |
2017-03-29 | - | Årsstämma |
2017-01-26 | - | Bokslutskommuniké 2016 |
2016-10-18 | - | Kvartalsrapport 2016-Q3 |
2016-07-14 | - | Kvartalsrapport 2016-Q2 |
2016-04-22 | - | Kvartalsrapport 2016-Q1 |
2016-03-31 | - | X-dag ordinarie utdelning |
2016-03-30 | - | Årsstämma |
2016-01-28 | - | Bokslutskommuniké 2015 |
2015-10-15 | - | Kvartalsrapport 2015-Q3 |
2015-09-02 | - | Extra Bolagsstämma 2015 |
2015-07-15 | - | Kvartalsrapport 2015-Q2 |
2015-04-20 | - | Kvartalsrapport 2015-Q1 |
2015-03-26 | - | X-dag ordinarie utdelning GETI B 2.80 SEK |
2015-03-25 | - | Årsstämma |
2015-01-28 | - | Bokslutskommuniké 2014 |
2014-10-16 | - | Kvartalsrapport 2014-Q3 |
2014-10-16 | - | Analytiker möte 2014 |
2014-07-15 | - | Kvartalsrapport 2014-Q2 |
2014-04-16 | - | Kvartalsrapport 2014-Q1 |
2014-03-21 | - | X-dag ordinarie utdelning GETI B 4.15 SEK |
2014-03-20 | - | Årsstämma |
2014-01-28 | - | Bokslutskommuniké 2013 |
2013-10-15 | - | Kvartalsrapport 2013-Q3 |
2013-10-15 | - | Analytiker möte 2013 |
2013-10-15 | - | 15-7 2013 |
2013-07-11 | - | Kvartalsrapport 2013-Q2 |
2013-04-17 | - | Kvartalsrapport 2013-Q1 |
2013-03-22 | - | X-dag ordinarie utdelning GETI B 4.15 SEK |
2013-03-21 | - | Årsstämma |
2013-02-08 | - | Kapitalmarknadsdag 2013 |
2013-01-25 | - | Bokslutskommuniké 2012 |
2012-10-17 | - | Kvartalsrapport 2012-Q3 |
2012-10-17 | - | Analytiker möte 2012 |
2012-07-11 | - | Kvartalsrapport 2012-Q2 |
2012-04-19 | - | Kvartalsrapport 2012-Q1 |
2012-03-29 | - | X-dag ordinarie utdelning GETI B 3.75 SEK |
2012-03-28 | - | Årsstämma |
2012-01-26 | - | Bokslutskommuniké 2011 |
2011-10-20 | - | Kvartalsrapport 2011-Q3 |
2011-07-11 | - | Kvartalsrapport 2011-Q2 |
2011-04-28 | - | X-dag ordinarie utdelning GETI B 3.25 SEK |
2011-04-27 | - | Årsstämma |
2011-04-27 | - | Kvartalsrapport 2011-Q1 |
2011-01-28 | - | Kapitalmarknadsdag 2011 |
2011-01-26 | - | Bokslutskommuniké 2010 |
2010-10-19 | - | Kvartalsrapport 2010-Q3 |
2010-04-23 | - | X-dag ordinarie utdelning GETI B 2.75 SEK |
2010-04-22 | - | X-dag ordinarie utdelning GETI B 2.75 SEK |
2010-04-21 | - | Årsstämma |
2010-04-21 | - | Kvartalsrapport 2010-Q1 |
2010-01-26 | - | Bokslutskommuniké 2009 |
2009-07-13 | - | Kvartalsrapport 2009-Q2 |
2009-05-06 | - | Kvartalsrapport 2009-Q3 |
2009-04-22 | - | X-dag ordinarie utdelning GETI B 2.40 SEK |
2009-04-21 | - | Årsstämma |
2009-04-21 | - | Kvartalsrapport 2009-Q1 |
2008-04-18 | - | X-dag ordinarie utdelning GETI B 2.40 SEK |
2007-04-20 | - | X-dag ordinarie utdelning GETI B 2.20 SEK |
2006-04-21 | - | X-dag ordinarie utdelning GETI B 2.00 SEK |
2005-04-20 | - | X-dag ordinarie utdelning GETI B 1.65 SEK |
2004-04-22 | - | X-dag ordinarie utdelning GETI B 1.35 SEK |
2003-11-25 | - | Split GETI B 1:4 |
2003-04-24 | - | X-dag ordinarie utdelning GETI B 4.25 SEK |
2002-04-19 | - | X-dag ordinarie utdelning GETI B 3.75 SEK |
2001-04-24 | - | X-dag ordinarie utdelning GETI B 3.50 SEK |
2000-04-28 | - | X-dag ordinarie utdelning GETI B 3.50 SEK |
1999-04-22 | - | X-dag ordinarie utdelning GETI B 3.25 SEK |
1998-04-24 | - | X-dag ordinarie utdelning GETI B 2.75 SEK |
1997-04-30 | - | X-dag ordinarie utdelning GETI B 2.50 SEK |
1996-04-19 | - | X-dag ordinarie utdelning GETI B 6.00 SEK |
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The notified body, TÜV SÜD, is temporarily suspending the CE certificate for Getinge's Cardiosave Intra-Aortic Balloon Pump with immediate effect. Getinge is given six months to adhere to the required corrective actions. The financial impact is not expected to be material for Getinge.
As previously communicated by Getinge, the CE certificate for Getinge's subsidiary Datascope Corp. for the Cardiosave Intra-Aortic Balloon Pump, was reinstated by TÜV SÜD in July 2023 after approximately three months of suspension due to gaps identified in compliance with applicable regulation. This decision was complemented with conditions to be fulfilled to maintain the CE certificate. The certificate is mandatory for deliveries of Cardiosave in countries requiring CE certification.
TÜV SÜD has now evaluated the compliance with the conditions for Getinge and assessed that they are only partially fulfilled. Specifically, the notified body requests Getinge to accelerate implementation of committed product improvements and ongoing field safety corrective actions for Cardiosave. Component shortages, as Getinge has communicated about earlier, is one of the reasons for not meeting timeline to implement improvements.
Consequently, TÜV SÜD has decided to immediately suspend the CE certificate for six months. During the suspension, Getinge will not be able to provide intra-aortic balloon pumps to customers requiring the CE certificate, which represents approximately 100 MSEK of the annual sales of Cardiosave.
TÜV SÜD's decision does not affect the installed base of Cardiosave. This means, products already on the market can continue to be used and devices already in distribution can be delivered. Intra-Aortic Balloon catheters and spare parts are not affected by this decision.
"We are aware of the very problematic situation this suspension puts on healthcare providers and critically ill patients. Therefore, in close dialogue with TÜV SÜD, we are working urgently to minimize the impact. All affected customers will receive continuous information from us," says Elin Frostehav President Acute Care Therapies at Getinge.
In parallel with the efforts to regain the CE certificate for Cardiosave, Getinge is accelerating development of the next product generation.
Media contact:
Lars Mattson, Head of Investor Relations
Phone: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com
Caroline Örmgård, Head of Public & Media Relations
Phone: +46 (0)10 335 0041
Email: caroline.ormgard@getinge.com
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.